Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) has already been proven an efficient treatment option for type 2 diabetes. This combination can effectively improve glycated hemoglobin levels, cause weight loss and reduce the dosage of insulin. In addition, it can also reduce the risk of hypoglycemia. Several randomized controlled trials have confirmed that this treatment may be just as effective for type 1 diabetes mellitus (T1DM) patients. The objective of this meta-analysis was to assess the effects and efficacy of the treatment on glycemic changes, weight loss and insulin dosage in type 1 diabetes mellitus patients. METHODS: We searched Embase, PubMed and Cochrane for randomized controlled trials (no time restrictions) that investigated combined insulin and GLP-1 treatment. The main endpoints were measurements of glycated hemoglobin and changes in the weight and the dosage of insulin. RESULTS: In total, 1093 were studies identified, and 7 studies were included in our meta-analysis. GLP-1 agonist and insulin combination therapy led to greater reductions in HbA1c levels [P = 0.03; mean difference -0.21; 95% confidence intervals (CI) (-0.40, 0.02)] and weight [P < 0.05; -3.53 (-4.86, 2.19)] compared to control treatments. The combination therapy did not significantly influence the daily weight-adjusted total insulin dose [P = 0.05; -0.11 (-0.23, 0)], but it did reduce the daily weight-adjusted bolus insulin dose [P = 0.001; -0.06 (-0.1, 0.02)]. CONCLUSION: Our meta-analysis supports the use of a combined therapeutic regimen of insulin and GLP-1RAs for treating patients with T1DM. Combination therapy with GLP-1 and insulin could achieve an ideal treatment effect on glycemic control, weight loss and bolus insulin dose in patients with T1DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a meta-analysis by Wang and colleagues, a combination of GLP-1 RA and insulin therapy leads to a small but significantly more significant reduction in HbA1c than traditional treatment (−0.21 [−0.40 to −0.02]).34”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, differences in hypoglycemic events were not substantial or reduced in combination treatment, suggesting that combination treatment does not increase the risk of hypoglycemia.34”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“Still, several studies support their use in this population, with positive effects on glycemic control and a reduction in bolus insulin doses and weight.33,34”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“[24] performed the glucose clamp test on T1DM patients with negative C-peptide and reported that infusion of GLP-1 could reduce elevated postprandial blood glucose levels, reduce glucagon levels and increase glucose utilization [25].”
MethodFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1×
“Previous studies have demonstrated that GLP-1RAs promote the synthesis and secretion of insulin, stimulate the neogenesis of b-cells, increase the replication of b-cells and reduce b-cell apoptosis [21, 22].”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · cited 1×
“In addition, GLP-1 does not induce insulin secretion at low levels of blood glucose; therefore, it can effectively reduce both glycated hemoglobin levels and the risk of hypoglycemia [4, 5].”
BackgroundPerfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 383 · cited 3×
“Another homologous retrospective study reached the same conclusion regarding SBP [32], and a similar result was found in patients with T2DM [33–35].”
MethodType 1 diabetes: recent developments
Devendra, D., Liu, E., & Eisenbarth, G. S. (2004) · BMJ · doi:10.1136/bmj.328.7442.750 · Cited by 353
Creutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330 · cited 1×
“The effect of GLP-1 on fasting glucose in T1DM patients depends on blood glucose levels, glucagon levels and remaining b-cell function [23].”
BackgroundObesity and health-related quality of life: a cross-sectional analysis of the US population
Hassan, M. K., Joshi, A. V., Madhavan, S. S., & Amonkar, M. M. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802396 · Cited by 314 · cited 1×
“All included studies reported the same conclusion, and this change in weight may help improve the quality of life in patients with T1DM [28].”
BackgroundGedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A. D., Parkes, D. G., & Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 242
Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Dinneen, S., Alzaid, A., Turk, D., & Rizza, R. (1995) · Diabetologia · doi:10.1007/bf00400639 · Cited by 190 · cited 1×
“However, insulin cannot improve the excessive secretion of glucagon in patients with T1DM [2].”
BackgroundDejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Friedrichsen, B. N., Tornhave, D., Knudsen, L. B., & Petersen, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.013 · Cited by 170 · cited 1×
“Previous studies have demonstrated that GLP-1RAs promote the synthesis and secretion of insulin, stimulate the neogenesis of b-cells, increase the replication of b-cells and reduce b-cell apoptosis [21, 22].”
BackgroundKielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165 · cited 1×
“Most studies [15, 17, 27, 31], except for two [12, 16], concluded that this type of therapy could not effectively reduce the dosage of basal insulin.”
BackgroundFerdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E. M., Sager, P. T., Brunelle, R., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 145
Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin
Viswanathan, P., Chaudhuri, A., Bhatia, R., Al-Atrash, F., Mohanty, P., & Dandona, P. (2007) · Endocrine Practice · doi:10.4158/ep.13.5.444 · Cited by 142
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137 · cited 1×
“In addition, GLP-1 does not induce insulin secretion at low levels of blood glucose; therefore, it can effectively reduce both glycated hemoglobin levels and the risk of hypoglycemia [4, 5].”
BackgroundRother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133 · cited 3×
“Most studies [15, 17, 27, 31], except for two [12, 16], concluded that this type of therapy could not effectively reduce the dosage of basal insulin.”
BackgroundLiraglutide as additional treatment for type 1 diabetes
Varanasi, A., Bellini, N., Rawal, D., Vora, M., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0330 · Cited by 129 · cited 1×
“Our data showed an obvious improvement in HbA1c levels, which is consistent with several studies [13, 17, 26, 27]; nevertheless, other studies have not detected a statistically significant difference in the level of HbA1c [11, 12, 14–16].”
ResultFeatures of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes
Bergman, B. C., Howard, D., Schauer, I. E., Maahs, D. M., Snell-Bergeon, J. K., Eckel, R. H., Perreault, L., & Rewers, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3172 · Cited by 107
Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103 · cited 4×
“We excluded one study [14] based on the results of sensitivity analysis because the difference in baseline data between the experimental group and the control group interfered with the conclusion; this excluded paper’s Table 2 Forest plot showing the effect of combined glucagon-like peptide-1 receptor agonist (GLP-1RA…”
BackgroundMethodResultInfluentialNatural Course of Remission in IDDM During 1st yr After Diagnosis
Martin, S., Pawlowski, B., Greulich, B., Ziegler, A. G., Mandrup-Poulsen, T., & Mahon, J. (1992) · Diabetes Care · doi:10.2337/diacare.15.1.66 · Cited by 103 · cited 1×
“be due to the honeymoon phase in T1DM [13, 29], the suppression of glucagon or delayed”
BackgroundKumar, K. V. S. H., Shaikh, A., & Prusty, P. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.01.020 · Cited by 102 · cited 4×
“be due to the honeymoon phase in T1DM [13, 29], the suppression of glucagon or delayed”
BackgroundResultInfluentialKuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101 · cited 11×
“Possible mechanisms include (1) reduced intake of carbohydrates due to delayed gastric emptying caused by the GLP-1 agonist [17], (2) improved insulin sensitivity, (3) stabilization of the daily fluctuation of glucose levels, (4) promotion of the synthesis and secretion of insulin, (5) suppressed glucagon secretion an…”
BackgroundMethodResultInfluentialIDRIS, I. R., Patiag, D., Gray, S., & Donnelly, R. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00924-8 · Cited by 95
Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
Behme, M. T., Dupré, J., & McDonald, T. J. (2003) · BMC Endocrine Disorders · doi:10.1186/1472-6823-3-3 · Cited by 88
Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus
Kuhadiya, N. D., Malik, R., Bellini, N. J., Patterson, J. L., Traina, A. N., Makdissi, A., & Dandona, P. (2013) · Endocrine Practice · doi:10.4158/ep13065.or · Cited by 81 · cited 2×
“Frandsen and Kuhadiya’s studies also discussed the role of GLP-1RA and insulin combination therapy on systolic blood pressure (SBP) [12, 17], showing an identical mean reduction of 3 mm of mercury (mmHg), compared to control treatments.”
ResultExenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes
Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I. (2014) · Diabetes Care · doi:10.2337/dc13-1473 · Cited by 74 · cited 3×
“Most studies [15, 17, 27, 31], except for two [12, 16], concluded that this type of therapy could not effectively reduce the dosage of basal insulin.”
BackgroundMethodDavies, M. J., Kela, R., & Khunti, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66
Type 1 Diabetes Treatment beyond Insulin: Role of GLP-1 Analogs
Harrison, L. B., Mora, P. F., Clark, G. O., & Lingvay, I. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318279b7d6 · Cited by 46 · cited 2×
“Our data showed an obvious improvement in HbA1c levels, which is consistent with several studies [13, 17, 26, 27]; nevertheless, other studies have not detected a statistically significant difference in the level of HbA1c [11, 12, 14–16].”
BackgroundResultRole of Receptor-Interacting Protein 140 in human fat cells
Mejhert, N., Laurencikiene, J., Pettersson, A., Kaaman, M., Stenson, B. M., Rydén, M., & Dahlman, I. A. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-1 · Cited by 39
Research works printed but not linked: 1
- Hamamoto Y, Mori K, Honjo S, et al. One-year effects of liraglutide on pancreatic beta cell function and glycemic control in Japanese type 1 diabetes with residual insulin secretion. Diabetologia. 2012;55:S300.
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
“2%) reductions in A1C compared with insulin alone in people with type 1 diabetes and also reduced body weight by;3 kg (31).”
Method9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
“2%) reductions in A1C compared with insulin alone in people with type 1 diabetes and also reduced body weight by ;3 kg (29).”
Method9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Quattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 244
Metadata
- Authors
- Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P.
- Affiliations
- Tianjin Medical University (CN)
- Corresponding author
- Yu, Pei
- Venue
- Diabetes Therapy
- Published
- 2017-06-14
- Volume
- 8
- Issue
- 4
- Pages
- 727-738
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC5544618
- OpenAlex
- W2626839453
- Cited by
- 70
- References
- 38
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 6 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 2 · 2018: 6 · 2017: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Tianjin Health Industry Key Research Projects (15KG101)
- Tianjin Science and Technology Support Project (13ZCDSY01300)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, insulin, GLP-1 receptor agonists, combination therapy, glycemic control, HbA1c, weight loss, insulin dose reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

